Meropenem/Vaborbactam

Mechanism :

Meropenem: Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins
Vaborbactam is a beta-lactamase inhibitor that protects meropenem from degradation by certain serine beta-lactamases (e.g., K. pneumonia carbapenemase [KPC]).

Indication :

Treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex in patients ≥18 years of age.

Contraindications :

Hypersensitivity to meropenem, vaborbactam, other carbapenems or beta-lactamase inhibitors, or any component of the formulation; patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial agents.

Dosing :

Safety and efficacy not established in pediatric population.

Adults:

4 g (2 g meropenem and 2 g vaborbactam) IV every 8 hours for up to 14 days.

Adverse Effect :

Phlebitis, headache, hypokalemia, diarrhea, nausea, increased serum AST/ALT, hypersensitivity, infusion site reaction, fever.

Interaction :

Probenecid: May increase the serum concentration of Meropenem.
Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.

Hepatic Dose :

No dosage adjustments are recommended.